BTI vs MDLZ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BTI's deterministic health score is stable with a Piotroski F-Score of 6/9, indicating moderate financial strength, though the absence of an Altman Z-Score limits distress risk assessment. The stock trades significantly above its Graham Number of $34.30 at $59.16, reflecting a rich valuation despite declining revenue and a concerning 168.95% dividend payout ratio. Strong operating margins and a high dividend yield provide support, but deteriorating growth and weak technicals (10/100) offset these advantages. Analysts recommend a buy with a near-current target price, suggesting limited upside.
MDLZ presents a conflicted profile with a stable Piotroski F-Score of 4/9 but severe valuation gaps, trading at $57.42 against a Graham Number of $29.28 and an Intrinsic Value of $13.23. While revenue growth remains robust at 9.3%, the company is facing a critical earnings collapse (-60.4% YoY) and an unsustainable dividend payout ratio of 102.65%. The strong analyst 'buy' consensus and consistent earnings beat history are offset by poor liquidity ratios and a bearish technical trend.
Compare Another Pair
Related Comparisons
BTI vs MDLZ: Head-to-Head Comparison
This page compares British American Tobacco p.l.c. (BTI) and Mondelez International, Inc. (MDLZ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.